Respiratory biologics is an emerging area in pharmaceutical development, accounting for approximately 10% of biologics currently in the pipeline. These innovative treatments offer significant benefits across various therapeutic areas. Gain deeper insights into the development of inhaled biologics with this comprehensive presentation by experts from Kindeva Drug Delivery, Aerogen Pharma, and Cystetic Medicines.
Highlights include:
- Influences of dose/regimen, physical/chemical properties, and patient/commercial needs on technology during development
- The role of respiratory biologics in advancing vaccine development
- How inhaled biologics compare to injected biologics
- Important considerations and advantages in the development of both wet and dry formulations
John Patton
Head Kindeva SAB
Kindeva Drug Delivery
Keith Ung
Director and Bay Area Site Head
Kindeva Drug Delivery
Andy Clark
President and General Manager
Aerogen Pharma Corporation
Jeff Weers
Chief Technology Officer
Cystetic Medicines, Inc.
Download the Webinar
Fields marked with an * are required.